PDS Biotechnology Corpora...

AI Score

0

Unlock

1.39
-0.03 (-2.11%)
At close: Jan 14, 2025, 3:59 PM
1.39
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 1.31
Market Cap 52.00M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.17
PE Ratio (ttm) -1.19
Forward PE n/a
Analyst Buy
Ask 1.5
Volume 159,657
Avg. Volume (20D) 421,949
Open 1.45
Previous Close 1.42
Day's Range 1.35 - 1.48
52-Week Range 1.30 - 6.68
Beta undefined

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclini...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 30, 2015
Employees 25
Stock Exchange NASDAQ
Ticker Symbol PDSB

Analyst Forecast

According to 3 analyst ratings, the average rating for PDSB stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 907.19% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-18.48%
PDS Biotechnology shares are trading lower after t... Unlock content with Pro Subscription
9 months ago · Source
-14.06%
PDS Biotechnology shares are trading lower. The company reported Q4 financial results.